The Australian share market is a great place to build a retirement portfolio.
But which ASX retirement shares are in the buy zone right now? Three quality options that could be worth considering are listed below. Here's what you need to know about them:
Aspen Group Limited (ASX: APZ)
The first ASX retirement share that could be a buy is Aspen Group. It is a leading provider of quality affordable accommodation across residential, land lease, and holiday park communities.
The team at Bell Potter rates the company highly. So much so, the broker has named it on its coveted Australian equities panel again this month. It likes Aspen Group due to its sector agnostic, high return on equity focus on sub-sectors that are non-fungible and repeatable over time.
In addition, the broker likes that Aspen's management has plenty of skin in the game and that its "valuation is undemanding."
The broker has a buy rating and $2.75 price target on its shares.
In respect to income, Bell Potter is forecasting some attractive dividend yields from its shares. It has pencilled in yields of 4% in FY 2025 and 4.1% in FY 2026.
Coles Group Ltd (ASX: COL)
Another ASX retirement share that analysts are positive on is supermarket giant Coles.
It could be a good option due to its defensive qualities, which were on display for all to see during the COVID pandemic.
Bell Potter likes the company and also has it on its Australian equities panel. Its analysts highlight that they "continue to see COL as providing an attractive earnings growth profile through to FY27e on an underlying basis."
The broker currently has a buy rating and $20.50 price target on its shares.
As for income, Bell Potter is expecting Coles to pay fully franked dividends of 68 cents per share in FY 2025 and then 78 cents per share in FY 2026. This represents yields of 3.7% and 4.2%, respectively.
CSL Limited (ASX: CSL)
A final ASX retirement share to consider buying is CSL.
It is the biotechnology company behind the CSL Behring, CSL Vifor, and CSL Seqirus businesses. These are leaders in their respective fields of plasma therapies, iron deficiency, and vaccines.
While CSL doesn't provide much by way of income, it has the potential to compound significantly in the future. This is due to its positive growth outlook, which is being underpinned by strong demand for its plasma therapies and margin expansion.
Citi is a big fan of the company and recently put a buy rating and $345.00 price target on its shares.
